SCCF-177J clone#8
IMBAi002-A
General
Cell Line |
|
| hPSCreg name | IMBAi002-A |
| Cite as: | IMBAi002-A (RRID:CVCL_C1Q9) |
| Alternative name(s) |
SCCF-177J clone#8
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines |
IMBAi002-B (SCCF-177J clone#4) IMBAi002-C (SCCF-177J clone#6) |
| Last update | 28th August 2024 |
| User feedback | |
Provider |
|
| Generator | Institute of Molecular Biotechnology (IMBA) |
| Owner | Institute of Molecular Biotechnology (IMBA) |
| Distributors | |
| Derivation country | Austria |
External Databases |
|
| BioSamples | SAMEA110271770 |
| Cellosaurus | CVCL_C1Q9 |
| Wikidata | Q114311729 |
General Information |
|
| Publications |
|
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: allowed
|
Donor Information
General Donor Information |
|
| Sex | female |
| Ethnicity | Caucasian |
Phenotype and Disease related information (Donor) |
|
| Diseases | No disease was diagnosed.
|
| Disease associated phenotypes | no phenotypes |
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
Yes
|
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
Yes
WGS
https://ega-archive.org/studies/EGAS00001006262 WGS data from healthy reference iPSC lines. The median coverage is 41-50x. >85% have a coverage of >30x. 97% of the variants are known. |
Donor Relations |
|
| Other cell lines of this donor | |
External Databases (Donor) |
|
| BioSamples | SAMEA110271772 |
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | Yes |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | No |
| If you do not hold the Donor Consent Form, do you know who does? | Yes |
| Please provide the contact information |
Stary Georg |
| Alternatives to consent are available? | Yes |
| Alternatives to consent | A new version of the donor consent has been signed. |
| Alternative consent approval number | |
| Is there other documentation provided to the donor for consenting purposes? | No |
| Confirm that consent was obtained by a qualified professional | Yes |
| Has the donor agreed to be re-contacted? | Unknown |
| Has the donor been informed about how her/his data will be protected? | Yes |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
| Does consent expressly prevent the derivation of pluripotent stem cells? | No |
| Does consent pertain to a specific research project? | No |
| Does consent permit unforeseen future research, without further consent? | No |
| Does the consent permit uses of donated embryo/tissue or derived cell line intended for clinical treatment or human applications? | No |
| Does consent expressly prevent development of commercial products? | No |
| Does consent expressly prevent financial gain from any use of the donated embryo/tissue, including any product made from it? | Yes |
| Does consent expressly permit storage of donated embryo/tissue for an unlimited time? | Yes |
| Does consent expressly permit storage of cells derived from the donated embryo/tissue for an unlimited time? | Yes |
| Does consent prevent the DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | Yes |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
Does consent permit research by | |
| an academic institution? | Yes |
| a public organisation? | Yes |
| a non-profit company? | Yes |
| a for-profit corporation? | Yes |
| Does consent expressly permit collection of genetic information? | Yes |
| Does consent expressly permit storage of genetic information? | Yes |
| Does consent prevent dissemination of genetic information? | Yes |
| Has the donor been informed that their donated biosample or derived cells may be tested for the presence of microbiological agents / pathogens? | No |
| How may genetic information associated with the cell line be accessed? | Controlled Access |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Does the consent anticipate that the donor will be notified of results or outcomes of any research involving the donated samples or derived cells? | No |
| Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? | Yes |
| Does the consent permit the donor, upon withdrawal of consent, to stop delivery or use of information and data about the donor? | No |
| Does consent permit access to medical records of the donor? | No |
| Does consent permit access to any other source of information about the clinical treatment or health of the donor? | No |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | Ethikkommission der Medizinischen Universität Wien |
| Approval number | MUW EK 1596/2017 |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | Yes |
| Name of accrediting authority involved? | Ethikkommission der Medizinischen Universität Wien |
| Approval number | MUW EK 1596/2017 |
| Do you have obligations to third parties in regard to the use of the cell line? | Yes |
| Please describe: | Cyto TuneTM Limited Use Label License, iPS Academia Japan User Notice,Sigma-Aldrich CRISPR Limited Label Use License Agreement |
| Are you aware of any further constraints on the use of the donated embryo/tissue or derived cells? | No |
| Is there an MTA available for the cell line? | Yes |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | CytoTune™-iPS 2.0 Sendai Reprogramming Kit |
| Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? | No |
hIPSC Derivation
General |
|
| Source cell type |
Synonyms
|
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Sendai virus |
| Is reprogramming vector detectable? |
No |
| Methods used |
RT-PCR
|
Vector free reprogramming |
|
Other |
|
| Selection criteria for clones | Morphology |
| Derived under xeno-free conditions |
No |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
Culture Conditions
| Surface coating | Matrigel/Geltrex |
| Feeder cells |
No |
| Passage method |
Enzyme-free cell dissociation
Gentle Cell Dissociation Reagent
|
| Medium |
Other medium:
Base medium: StemFlex™ Medium - Thermo Fisher Scientific
Main protein source: Serum concentration: % |
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| Alkaline Phosphatase |
Yes |
|
|
|||
| SOX2 |
Yes |
|
||||
| NANOG |
Yes |
|
||||
| POU5F1 (OCT-4) |
Yes |
|
Differentiation Potency
In vitro directed differentiation
Cardioids
Morphology
Hofbauer et al., 2021 Figure S1. Generation and functional characterization of cardiac chamber-like structures
Cerebral Organoids
Microbiology / Virus Screening |
|
| HIV 1 | Negative |
| HIV 2 | Negative |
| Hepatitis B | Negative |
| Hepatitis C | Negative |
| Mycoplasma | Negative |
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
|
Other Genotyping (Cell Line) |
|
| Is there genome-wide genotyping or functional data available? |
Yes
Whole genome sequencing (WGS)
https://ega-archive.org/studies/EGAS00001006262 WGS data from healthy reference iPSC lines. The median coverage is 41-50x. >85% have a coverage of >30x. 97% of the variants are known. |
Login to share your feedback, experiences or results with the research community.